Epoetin beta
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| |
| Identifiers | |
 | |
| B03XA01 | |
| UNII |
64FS3BFH5W  |
| Chemical data | |
| (what is this?) (verify) | |
Epoetin beta (rINN) /ɛˈpoʊ.ɨtɨn/ is a synthetic, recombinant[1] form of erythropoietin. It stimulates erythropoiesis (increases red blood cell levels) and is used to treat anemia, commonly associated with chronic renal failure and cancer chemotherapy.
Epoetin is marketed under the trade names NeoRecormon.[2]
References
- ↑ Dunn CJ, Markham A (1996). "Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure". Drugs 51 (2): 299–318. doi:10.2165/00003495-199651020-00008. PMID 8808169.
- ↑ Amgen - Products. URL: http://www.amgen.com/patients/prca.html. Accessed on: October 21, 2007.
External links
- Jenkins, John K. (2007-06-26). "Congressional Testimony: Erythropoiesis-Stimulating Agents (ESA)". News & Events. FDA. Retrieved 2010-02-25.